A Phase 1, Open-Label Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of [14C] Pacritinib Following a Single Oral Dose in Healthy Male Subjects

Trial Profile

A Phase 1, Open-Label Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of [14C] Pacritinib Following a Single Oral Dose in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2016

At a glance

  • Drugs Pacritinib (Primary)
  • Indications Myelofibrosis
  • Focus Pharmacokinetics
  • Sponsors CTI BioPharma
  • Most Recent Events

    • 20 Apr 2016 Pharmacokinetic results (n=6) presented at the 107th Annual Meeting of the American Association for Cancer Research.
    • 20 Apr 2016 Results published in the CTI BioPharma media release.
    • 14 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top